Skip to content

Journey Medical Corporation DERM Amortization Of Debt Discount Premium

Amortization Of Debt Discount Premium at other companies

PTH
Pelthos Therapeutics Inc.PTHS

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's amortization of debt discount premium.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's amortization of debt discount premium?
Journey Medical Corporation (DERM) reported amortization of debt discount premium of $96K in Q1 2026.
How has Journey Medical Corporation's amortization of debt discount premium changed year-over-year?
Journey Medical Corporation's amortization of debt discount premium decreased by 5.0% year-over-year, from $101K to $96K.
What is the long-term trend for Journey Medical Corporation's amortization of debt discount premium?
Over 3 years (2022 to 2025), Journey Medical Corporation's amortization of debt discount premium has grown at a 94.8% compound annual growth rate (CAGR), from $63K to $466K.